Apnimed, the company behind what could become the first oral pharmacotherapy for obstructive sleep apnea (OSA), has filed for an initial public offering in the United States. The company is expected to list on Nasdaq under the ticker $APMD. The filing comes at a notable moment for the biotech sector. […]
Obstructive Sleep Apnea
LivaNova Shares Positive 12-Month Results From Obstructive Sleep Apnea Study
Recently published study results demonstrate the efficacy of LivaNova Plc’s aura6000 System in treating moderate to severe obstructive sleep apnea (OSA). Published in Annals of Internal Medicine, the full 12-month results from the company’s OSPREY randomized controlled trial (RCT) demonstrate the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality. Overall, the study authors concluded that pHGNS for OSA yielded clinically significant improvements versus […]
ProSomnus and MonitAir Collaborate to Enhance Connected Care for OSA
ProSomnus Sleep Technologies (“ProSomnus”), pioneer of Smart Sleep Medicine™, and MonitAir, LLC (“MonitAir”), the premier digital health and tele-monitoring platform for sleep medicine announced a collaboration to support connected, longitudinal and personalized care for patients with obstructive sleep apnea (OSA). Through this collaboration, healthcare providers who prescribe a ProSomnus RPMO₂ […]
New Study Shows Inspire Therapy Helps Reduce Hypoxic Burden
Inspire Medical Systems, Inc. participated in SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS) on June 14–17 in Baltimore, Maryland. SLEEP is the premier global forum for sleep medicine and research, jointly hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research […]
Philips Expands DreamStation Access for Lower-Weight Patients
Philips announced that Philips Respironics DreamStation BiPAP AVAPS devices, which include S, T, S/T, and PC modes with AVAPS, are available for sale in the United States for new set-ups for patients with obstructive sleep apnea (OSA) and respiratory impairment, who are both >7 years of age and weighing 40-66lbs. The […]
Mount Sinai Develops AI Tool to Predict Cardiovascular Risk in OSA
Mount Sinai researchers have created an analytic tool using machine learning that can predict cardiovascular disease risk in millions of patients with obstructive sleep apnea, a serious sleep disorder, according to findings recently published in Communications Medicine. The team said their study is the first to provide estimates of whether […]
Sunrise’s AI-Powered Measure of Respiratory Effort, REMOV, Better Reflects OSA Symptoms Than Traditional PSG Metrics
Sunrise Group, a pioneer in medical device innovation and sleep care, today announced a new peer-reviewed study in Nature Communications Medicine. Sunrise developed the only home sleep test with respiratory effort measurement that has been validated against esophageal pressure, the reference standard. The study reveals that REMOV, the Sunrise-specific marker […]
Inogen Launches Aurora CPAP Masks
Inogen, Inc. has announced the launch of Aurora CPAP masks, a new product in its expanding portfolio. Aurora’s introduction marks a significant milestone in Inogen’s strategy to expand its respiratory care portfolio and now bring quality, high-performing masks to patients indicated for obstructive sleep apnea (OSA). Strategic Positioning and Market […]
FDA Clears Kricket Positive Airway Pressure Device with KPAP
SleepRes, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Kricket PAP device, powered by Kairos Positive Airway Pressure (KPAP)™ for the treatment of obstructive sleep apnea (OSA) in patients weighing more than 66 lbs. The SleepRes PAP system is intended for home, hospital/institutional, […]
A New Piece of the Puzzle
For the millions of people managing both obesity and obstructive sleep apnea (OSA), tirzepatide (Zepbound® and Mounjaro®, Eli Lilly and Co.) may offer a welcome approach to help reduce symptoms and improve overall health and quality of life. It’s been almost exactly a year since investigators of the SURMOUNT-OSA trial […]













